Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/13987
Title: Prognostic value of transthoracic doppler echocardiography coronary flow velocity reserve in patients with asymmetric hypertrophic cardiomyopathy
Authors: Tesic, Milorad
Beleslin B.
Giga V.
Jovanovic, Ivana
Marinkovic J.
Zamaklar-Trifunović D.
Petrovic O.
Dobric M.
Aleksandrić S.
Juricic S.
Bošković N.
Tomasević M.
Ristić Fira A.
Orlic D.
Stojković A.
Vukcevic V.
Stankovic, Goran
Ostojic M.
Djordjević-Dikić A.
Journal: Journal of the American Heart Association
Issue Date: 19-Oct-2021
Abstract: BACKGROUND: Microvascular dysfunction might be a major determinant of clinical deterioration and outcome in patients with hypertrophic cardiomyopathy (HCM). However, long-term prognostic value of transthoracic Doppler echocardiography (TDE) coronary flow velocity reserve (CFVR) on clinical outcome is uncertain in HCM patients. Therefore, the aim of our study was to assess long-term prognostic value of CFVR on clinical outcome in HCM population. METHODS AND RESULTS: We prospectively included 150 HCM patients (82 women; mean age 48±15 years). Patients’ clinical characteristics, echocardiographic and CFVR findings (both for left anterior descending [LAD] and posterior descending artery [PD]), were assessed in all patients. The primary outcome was a composite of: HCM related death, heart failure requir-ing hospitalization, sustained ventricular tachycardia and ischemic stroke. Patients were stratified into 2 subgroups depend-ing on CFVR LAD value: Group 1 (CFVR LAD>2, [n=87]) and Group 2 (CFVR LAD≤2, [n=63]). During a median follow-up of 88 months, 41/150 (27.3%) patients had adverse cardiac events. In Group 1, there were 8/87 (9.2%), whereas in Group 2 there were 33/63 (52.4%, P<0.001 vs. Group 1) adverse cardiac events. By Kaplan-Meier analysis, patients with preserved CFVR LAD had significantly higher cumulative event-free survival rate compared to patients with impaired CFVR LAD (96.4% and 90.9% versus 66.9% and 40.0%, at 5 and 8 years, respectively: log-rank 37.2, P<0.001). Multivariable analysis identified only CFVR LAD≤2 as an independent predictor for adverse cardiac outcome (HR 6.54; 95% CI 2.83–16.30, P<0.001), while CFVR PD was not significantly associated with outcome. CONCLUSIONS: In patients with HCM, impaired CFVR LAD (≤2) is a strong, independent predictor of adverse cardiac outcome. When the aim of testing is HCM risk stratification and CFVR LAD data are available, the evaluation of CFVR PD is redundant.
URI: https://scidar.kg.ac.rs/handle/123456789/13987
Type: article
DOI: 10.1161/JAHA.120.021936
SCOPUS: 85119303739
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

39

Downloads(s)

6

Files in This Item:
File Description SizeFormat 
10.1161-JAHA.120.021936.pdf587.41 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.